Skip to main content
OpenTrials
Completed

NCT Number: NCT07213518

High Velocity Nasal Insufflation Versus Continuous Positive Airway Pressure in COVID 19 Pneumonic Patients

compare the efficacy of High-Velocity Nasal Insufflation (HVNI) versus Continuous Positive Airway Pressure (CPAP) in managing COVID 19 pneumonic patients with acute type 1 respiratory failure

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Pneumonia Respiration Disorders Respiratory Insufficiency Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mohamed AbdElmoniem

Al Mansurah, 35516, Egypt

About this study

A prospective randomized controlled trial was conducted on 108 patients with COVID 19 pneumonia with acute hypoxemic respiratory failure at Mansoura University Hospitals to compare the efficacy of High-Velocity Nasal Insufflation (HVNI) versus Continuous Positive Airway Pressure (CPAP) in managing COVID 19 pneumonic patients with acute type 1 respiratory failure, focusing on the need for invasive mechanical ventilation (IMV) and 28-day mortality. Patients were randomized into two equal groups: HVNI group and CPAP group. Baseline characteristics, respiratory parameters, and clinical outcomes were recorded.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged above 18 years with COVID 19 pneumonia with acute type 1 respiratory failure were included.

Exclusion criteria

  • patients with hypercapnic respiratory failure.
  • patients with a disturbed level of consciousness and/or a high risk of aspiration
  • individuals with hypotension
  • patients requiring invasive mechanical ventilation.

Treatment and study plan

High Velocity Nasal Insufflation

Device

COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure received High Velocity Nasal Insufflation

Continuous Positive Airway Pressure

Device

COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure received Continuous Positive Airway Pressure

Primary outcomes

  1. Correction of hypoxia in COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure

    Time frame: 6 months

    assessment of efficacy of High Velocity Nasal Insufflation versus Continuous Positive Airway Pressure in COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure

Sponsors and collaborators

Lead sponsor

Mansoura University

Other

Registry information

Official study title

High Velocity Nasal Insufflation Versus Continuous Positive Airway Pressure in COVID 19 Pneumonic Patients With Acute Type 1 Respiratory Failure

Important dates

Study start
2022
Primary completion
2022
Study completion
2023
First posted
Oct 9, 2025
Registry last updated
Oct 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.